- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Scinai Immunotherapeutics Ltd ADR (SCNI)
Scinai Immunotherapeutics Ltd ADR stock price live, this page displays NASDAQ SCNI stock exchange data. View the SCNI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Scinai Immunotherapeutics Ltd ADR real time stock price chart below.
What Is the Scinai Immunotherapeutics Ltd ADR Stock Price Today?
The Scinai Immunotherapeutics Ltd ADR stock price today is 2.600.
What Is the Stock Symbol for Scinai Immunotherapeutics Ltd ADR?
The stock symbol for Scinai Immunotherapeutics Ltd ADR is "SCNI."
What Stock Exchange Does Scinai Immunotherapeutics Ltd ADR Trade On?
Scinai Immunotherapeutics Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Scinai Immunotherapeutics Ltd ADR a Good Stock to Buy?
Determining whether Scinai Immunotherapeutics Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SCNI quote. (ISIN: US09073Q4029)
What Is the Scinai Immunotherapeutics Ltd ADR Stock Price Today?
The Scinai Immunotherapeutics Ltd ADR stock price today is 2.600.
What Is the Stock Symbol for Scinai Immunotherapeutics Ltd ADR?
The stock symbol for Scinai Immunotherapeutics Ltd ADR is "SCNI."
What Stock Exchange Does Scinai Immunotherapeutics Ltd ADR Trade On?
Scinai Immunotherapeutics Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Scinai Immunotherapeutics Ltd ADR a Good Stock to Buy?
Determining whether Scinai Immunotherapeutics Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SCNI quote. (ISIN: US09073Q4029)
2.600
+0.100(+4.00%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.430
2.610
52 wk Range
2.147
16.800
SCNI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.4302.610
52 wk Range
2.14716.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SCNI Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Scinai Immunotherapeutics Ltd ADR Earnings Call Summary for Q2/2026
- H1 2026 revenue rose 22.7% to $949K following Recipharm Israel acquisition, but operating loss hit $4.6M and gross loss reached $2.37M.
- Reported net income of $1.57M driven by one-time $6.4M bargain purchase gain; underlying business remains unprofitable with -252% gross margin.
- Cash position stands at $2.85M as of June 30; committed customer orders total $3.1M with $2.1M invoiced, raising liquidity concerns amid dilution risk.
- Management maintains 2026 CDMO revenue target of $5M, contingent on project execution and converting customer commitments into recognized revenue.
- CEO emphasized strategic shift post-acquisition, combining immunology R&D with manufacturing capabilities while prioritizing non-dilutive funding options.
Last Updated: 2026-08-26, 11:42 a/m
Read Full TranscriptEarnings
Latest Release
Jun 15, 2026
EPS / Forecast
0.94 / --
Revenue / Forecast
489K / --
Compare SCNI to Peers and Sector
Metrics to compare | SCNI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSCNIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −4.2x | −0.4x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | 0.2x | 2.3x | 2.6x | |
Price / LTM Sales | 1.0x | 11.4x | 3.1x | |
Upside (Analyst Target) | - | 146.2% | 49.4% | |
Fair Value Upside | Unlock | −16.5% | 6.8% | Unlock |
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
People Also Watch
FAQ
What Is the Scinai (SCNI) Stock Price Today?
The Scinai stock price today is 2.600 USD.
What Stock Exchange Does Scinai Trade On?
Scinai is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Scinai?
The stock symbol for Scinai is "SCNI."
What Is the Scinai Market Cap?
As of today, Scinai market cap is 1.430M USD.
What Is Scinai's Earnings Per Share (TTM)?
The Scinai EPS (TTM) is -4.892.
From a Technical Analysis Perspective, Is SCNI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Scinai Stock Split?
Scinai has split 3 times.
How Many Employees Does Scinai Have?
Scinai has 45 employees.
What is the current trading status of Scinai (SCNI)?
As of Sep 01, 2026, Scinai (SCNI) is trading at a price of 2.600 USD, with a previous close of 2.500 USD. The stock has fluctuated within a day range of 2.430 USD to 2.610 USD, while its 52-week range spans from 2.147 USD to 16.800 USD.
What Is the SCNI Premarket Price?
SCNI's last pre-market stock price is 2.430 USD. The pre-market share volume is 239.000, and the stock has decreased by -0.070, or -2.800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.